{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:00:08Z","timestamp":1760238008690,"version":"build-2065373602"},"reference-count":25,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"German Research Foundation","award":["WE2554\/13-1","WE2554\/15-1","WE2554\/17-1"],"award-info":[{"award-number":["WE2554\/13-1","WE2554\/15-1","WE2554\/17-1"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Hepatic fibrosis is a common type of liver disease that is attracting increasing attention of basic scientists and clinicians worldwide [...]<\/jats:p>","DOI":"10.3390\/cells11152403","type":"journal-article","created":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T21:52:48Z","timestamp":1659649968000},"page":"2403","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Special Issue on \u201cCellular and Molecular Mechanisms Underlying the Pathogenesis of Hepatic Fibrosis II\u201d"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3888-0931","authenticated-orcid":false,"given":"Ralf","family":"Weiskirchen","sequence":"first","affiliation":[{"name":"Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), RWTH University Hospital Aachen, D-52074 Aachen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/hep.32163","article-title":"LiverScreen Consortium Investigators. Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases","volume":"75","author":"Castera","year":"2022","journal-title":"Hepatology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"921","DOI":"10.12688\/f1000research.14841.1","article-title":"Recent advances in understanding liver fibrosis: Bridging basic science and individualized treatment concepts","volume":"7","author":"Weiskirchen","year":"2018","journal-title":"F1000Research"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1080\/17474124.2018.1530110","article-title":"An update on the recent advances in antifibrotic therapy","volume":"12","author":"Tacke","year":"2018","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/hep.32285","article-title":"Hepatic fibrosis 2022: Unmet needs and a blueprint for the future","volume":"75","author":"Friedman","year":"2022","journal-title":"Hepatology"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Khanam, A., Saleeb, P.G., and Kottilil, S. (2021). Pathophysiology and Treatment Options for Hepatic Fibrosis: Can It Be Completely Cured?. Cells, 10.","DOI":"10.3390\/cells10051097"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Delgado, M.E., C\u00e1rdenas, B.I., Farran, N., and Fernandez, M. (2021). Metabolic Reprogramming of Liver Fibrosis. Cells, 10.","DOI":"10.3390\/cells10123604"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Smith-Cortinez, N., van Eunen, K., Heegsma, J., Serna-Salas, S.A., Sydor, S., Bechmann, L.P., Moshage, H., Bakker, B.M., and Faber, K.N. (2020). Simultaneous Induction of Glycolysis and Oxidative Phosphorylation during Activation of Hepatic Stellate Cells Reveals Novel Mitochondrial Targets to Treat Liver Fibrosis. Cells, 9.","DOI":"10.3390\/cells9112456"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Lafoz, E., Ruart, M., Anton, A., Oncins, A., and Hern\u00e1ndez-Gea, V. (2020). The Endothelium as a Driver of Liver Fibrosis and Regeneration. Cells, 9.","DOI":"10.3390\/cells9040929"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Kim, S.M., Hur, W.H., Kang, B.Y., Lee, S.W., Roh, P.R., Park, D.J., Sung, P.S., and Yoon, S.K. (2021). Death-Associated Protein 6 (Daxx) Alleviates Liver Fibrosis by Modulating Smad2 Acetylation. Cells, 10.","DOI":"10.3390\/cells10071742"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Geervliet, E., and Bansal, R. (2020). Matrix Metalloproteinases as Potential Biomarkers and Therapeutic Targets in Liver Diseases. Cells, 9.","DOI":"10.3390\/cells9051212"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Schippers, M., Post, E., Eichhorn, I., Langeland, J., Beljaars, L., Malo, M.S., Hodin, R.A., Mill\u00e1n, J.L., Popov, Y., and Schuppan, D. (2020). Phosphate Groups in the Lipid A Moiety Determine the Effects of LPS on Hepatic Stellate Cells: A Role for LPS-Dephosphorylating Activity in Liver Fibrosis. Cells, 9.","DOI":"10.3390\/cells9122708"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Claveria-Cabello, A., Colyn, L., Arechederra, M., Urman, J.M., Berasain, C., Avila, M.A., and Fernandez-Barrena, M.G. (2020). Epigenetics in Liver Fibrosis: Could HDACs be a Therapeutic Target?. Cells, 9.","DOI":"10.3390\/cells9102321"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Molenaar, M.R., Penning, L.C., and Helms, J.B. (2020). Playing Jekyll and Hyde-The Dual Role of Lipids in Fatty Liver Disease. Cells, 9.","DOI":"10.3390\/cells9102244"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Schwartz, B.E., Rajagopal, V., Smith, C., Cohick, E., Whissell, G., Gamboa, M., Pai, R., Sigova, A., Grossman, I., and Bumcrot, D. (2020). Discovery and Targeting of the Signaling Controls of PNPLA3 to Effectively Reduce Transcription, Expression, and Function in Pre-Clinical NAFLD\/NASH Settings. Cells, 9.","DOI":"10.3390\/cells9102247"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Drescher, H.K., Schippers, A., Rosenhain, S., Gremse, F., Bongiovanni, L., Bruin, A., Eswaran, S., Gallage, S.U., Pfister, D., and Szydlowska, M. (2020). L-Selectin\/CD62L is a Key Driver of Non-Alcoholic Steatohepatitis in Mice and Men. Cells, 9.","DOI":"10.3390\/cells9051106"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Heinrichs, D., Brandt, E.F., Fischer, P., K\u00f6hncke, J., Wirtz, T.H., Guldiken, N., Djudjaj, S., Boor, P., Kroy, D., and Weiskirchen, R. (2021). Unexpected Pro-Fibrotic Effect of MIF in Non-Alcoholic Steatohepatitis Is Linked to a Shift in NKT Cell Populations. Cells, 10.","DOI":"10.3390\/cells10020252"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Lin, H.Y., Yang, Y.L., Wang, P.W., Wang, F.S., and Huang, Y.H. (2020). The Emerging Role of MicroRNAs in NAFLD: Highlight of MicroRNA-29a in Modulating Oxidative Stress, Inflammation, and Beyond. Cells, 9.","DOI":"10.3390\/cells9041041"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Markovic, J., Sharma, A.D., and Balakrishnan, A. (2020). MicroRNA-221: A Fine Tuner and Potential Biomarker of Chronic Liver Injury. Cells, 9.","DOI":"10.3390\/cells9081767"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Asimakopoulou, A., Engel, K.M., Gassler, N., Bracht, T., Sitek, B., Buhl, E.M., Kalampoka, S., Pino\u00e9-Schmidt, M., van Helden, J., and Schiller, J. (2020). Deletion of Perilipin 5 Protects Against Hepatic Injury in Nonalcoholic Fatty Liver Disease via Missing Inflammasome Activation. Cells, 9.","DOI":"10.3390\/cells9061346"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Cierpka, R., Weiskirchen, R., and Asimakopoulos, A. (2021). Perilipin 5 Ameliorates Hepatic Stellate Cell Activation via SMAD2\/3 and SNAIL Signaling Pathways and Suppresses STAT3 Activation. Cells, 10.","DOI":"10.3390\/cells10092184"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Wu, H., Chen, C., Ziani, S., Nelson, L.J., \u00c1vila, M.A., Nevzorova, Y.A., and Cubero, F.J. (2021). Fibrotic Events in the Progression of Cholestatic Liver Disease. Cells, 10.","DOI":"10.3390\/cells10051107"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Hahn, L., Helmrich, N., Herebian, D., Mayatepek, E., Drebber, U., Domann, E., Olejniczak, S., Weigel, M., Hain, T., and Rath, T. (2020). IL-13 as Target to Reduce Cholestasis and Dysbiosis in Abcb4 Knockout Mice. Cells, 9.","DOI":"10.3390\/cells9091949"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Caligiuri, A., Gentilini, A., Pastore, M., Gitto, S., and Marra, F. (2021). Cellular and Molecular Mechanisms Underlying Liver Fibrosis Regression. Cells, 10.","DOI":"10.3390\/cells10102759"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Kundu, A., Dey, P., Park, J.H., Kim, I.S., Kwack, S.J., and Kim, H.S. (2020). EX-527 Prevents the Progression of High-Fat Diet-Induced Hepatic Steatosis and Fibrosis by Upregulating SIRT4 in Zucker Rats. Cells, 9.","DOI":"10.3390\/cells9051101"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Reichert, D., Adolph, L., K\u00f6hler, J.P., Buschmann, T., Luedde, T., H\u00e4ussinger, D., and Kordes, C. (2021). Improved Recovery from Liver Fibrosis by Crenolanib. Cells, 10.","DOI":"10.3390\/cells10040804"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/15\/2403\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:03:59Z","timestamp":1760141039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/15\/2403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,4]]},"references-count":25,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["cells11152403"],"URL":"https:\/\/doi.org\/10.3390\/cells11152403","relation":{},"ISSN":["2073-4409"],"issn-type":[{"type":"electronic","value":"2073-4409"}],"subject":[],"published":{"date-parts":[[2022,8,4]]}}}